Skip to content

Author

R. Kanesvaran

We have 4 of 449 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

The aim is to provide guidance for the optimisation and harmonisation of the management of patients with RCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials.

R. Kanesvaran, V. Gruenwald, A. Wong et al. · 0 citations
Open access Sep 2026

Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma.

INTRODUCTION Spread through air spaces (STAS) is an adverse histologic feature in early-stage lung adenocarcinoma (LUAD) incorporated into the ninth edition TNM staging. Despite its clinical significance, the molecular features underlying STAS in stage 1 LUAD remain incompletely characterised. METHODS Patients with s...

S. Saw, Meng-Yuan Pang, C. Patteri et al. · 0 citations
Aug 2026

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

BACKGROUND Enfortumab vedotin (EV) has transformed treatment for advanced urothelial carcinoma (aUC), but outcomes vary. Machine learning (ML) with explainable artificial intelligence (XAI) may improve survival prediction. METHODS Data from 544 aUC patients receiving EV after platinum chemotherapy and immunotherapy (...

K. Sridharan, O. Fiala, G. Sivaramakrishnan et al. · 0 citations
Review Open access Aug 2026

IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations

An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.

D. Khanna, T. Dey, E. Blanchard-Cavagis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.